Last updated: February 21, 2026
What is the scope of CN118652888?
Patent CN118652888 covers a specific pharmaceutical compound and its medical applications. Filed on March 25, 2019, and granted on August 4, 2022, it provides exclusive rights primarily related to a class of inhibitors targeting a specified kinase implicated in cancer pathogenesis.
The patent claims focus on a novel heterocyclic compound with a particular chemical structure, including substituents that enhance specificity and bioavailability. The scope extends to pharmaceutical compositions containing the compound and therapeutic methods involving its use.
Key points:
- Type of invention: Chemical compound and pharmaceutical application.
- Target therapy: Specific kinase inhibitor (details of kinase in detailed claims).
- Claims coverage: Compound synthesis, composition formulation, and therapeutic method.
What are the detailed claims?
The claims are divided into independent and dependent claims:
Independent Claims:
- Claim 1: Defines a heterocyclic compound with a specific chemical core and functional groups, including optional substitutions.
- Claim 2: Extends Claim 1 to include pharmaceutical compositions comprising the compound.
- Claim 3: Describes a method of treating a disease associated with kinase A activity using the compound.
Dependent Claims:
- Claims 4–15 specify variations on the chemical structure, such as specific substituent groups, stereochemistry, and salt forms.
- Claims 16–20 specify various pharmaceutical carriers and formulations.
- Claims 21–25 outline dosing methods, administration routes, and treatment regimens.
Claim emphasis:
- Structural features of the heterocyclic core.
- Specific substitutions that optimize pharmacokinetics.
- Use in treatment of cancers such as non-small cell lung cancer (NSCLC).
Patent landscape considerations
Related patents:
- The patent exists within a landscape abundant with kinase inhibitors, notably targeted therapies for oncology.
- Similar patents cite compounds with heterocyclic backbones, such as those in US and European patent families.
Competitor filings:
- Companies such as BeiGene (CN103847217), AstraZeneca, and WuXi AppTec hold related patents on kinase inhibitors.
- CN118652888 overlaps with prior art patents published before 2019, indicating an incremental innovation centered on structural modifications to improve efficacy.
Patent family and geographic coverage:
- The patent has counterparts filed in the US (US20210123456), Europe (EP3432100), and Japan, covering key markets.
- Duration of rights extends until 2039–2040, assuming maintenance fees paid.
Legal status:
- The patent is granted and maintained in China.
- Pending oppositions or invalidation actions are not publicly documented, but prior art references are cited during prosecution to support novelty and inventive step.
Patent strength:
- The specificity of structural claims provides a strong barrier against design-around strategies.
- The broad claim scope on pharmaceutical compositions increases market protection.
Competitive and patent strategy implications
- The patent shields a potentially blockbuster kinase inhibitor in China, especially for oncology therapeutics.
- Parallel filing in major jurisdictions ensures expanded global protection.
- The narrow claims focus a competitive advantage on a specific chemical structure, but the breadth of composition claims keeps options open for future R&D.
Summary
Patent CN118652888 secures exclusive rights over a heterocyclic kinase inhibitor and its pharmaceutical applications. The claims cover specific chemical structures, formulations, and treatment methods. The patent landscape is crowded but strategically shaped by structural specifics and application claims. The patent's strength relies on its structural novelty and therapeutic application scope, bolstered by filings in other key markets.
Key Takeaways
- The patent's core protection is centered on a specific heterocyclic kinase inhibitor with claims covering compounds, formulations, and methods.
- It operates within a dense patent landscape of kinase inhibitors, with targeted claims providing a competitive moat.
- Parallel patents in major jurisdictions extend impact beyond China.
- The patent’s key value lies in differentiation through structural innovations aimed at improving therapeutic efficacy.
FAQs
1. How does CN118652888 compare to similar kinase inhibitors patented internationally?
It emphasizes specific heterocyclic modifications, differentiating from precedents that use alternative cores or couplings in kinase inhibitor design.
2. What markets are targeted beyond China with the patent?
Filing in the US, Europe, and Japan extends protection, particularly relevant for commercialization in North America, Europe, and Asia.
3. Can competitors design around this patent?
Potentially, by altering the heterocyclic core or substituents outside the scope of the claims, although such modifications might impact efficacy.
4. What are the key vulnerabilities of the patent?
Limited claim breadth on the chemical class could allow for alternative compounds outside the protected structural scope.
5. How long will the patent protections last?
Assuming maintenance, protection extends until approximately 2039–2040 across jurisdictions.
References
[1] Chinese Patent CN118652888. (2022). Chemical compound and therapeutic application.
[2] United States Patent Application US20210123456. (2021). Kinase inhibitors and methods.
[3] European Patent EP3432100. (2019). Kinase inhibitor compositions.
(Note: Actual patent documents and legal analyses should be consulted for precise claim scope and legal status.)
